{"entity":{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","aka":[],"tldr":"Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML.","summary":"Andrew Wei was principal investigator of VIALE-C (venetoclax plus low-dose cytarabine) and first author of QUAZAR AML-001, which showed oral azacitidine maintenance improves survival after remission in older AML patients, the first maintenance therapy approved in AML. He leads the Australasian Leukaemia and Lymphoma Group AML programme and the venetoclax-based intensive chemotherapy trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20AH%5BAuthor%5D%20venetoclax%20azacitidine"}],"tags":["aml","venetoclax","australia"],"related":[],"cancers":["aml"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["peter-mac","wehi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne","institutionId":"peter-mac","specialisms":["Acute myeloid leukaemia","Venetoclax","Measurable residual disease","Maintenance therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20AH%5BAuthor%5D%20venetoclax%20azacitidine"}],"papers":[{"title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission (QUAZAR AML-001)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2004444"},{"title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial (VIALE-C)","journal":"Blood","year":2020,"doi":"10.1182/blood.2020004856"}],"orcid":"0000-0002-7514-3298"},"route":"/people/andrew-wei/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}